These are the stocks posting the largest moves before the bell.Market Insiderread more
But the bank's net interest margin, a key metric of bank profitability, falls short of expectations.Financeread more
Citi Research has an 18-item checklist to identify whether global markets are entering into a "bear period."Investingread more
The CEO of railroad operator CSX is sounding alarm on the U.S. economy, calling it "unusual" and "puzzling" as it weighs on the company's shipping volumes.Marketsread more
Ascending triangle patterns have been appearing across the stock market, and they tend to be precursors to higher prices, says Miller Tabak's Matt Maley.Trading Nationread more
"Here's what I think is true: Google refused to work for the Pentagon on artificial intelligence" and it works on AI in China, says Richard Clarke.Technologyread more
Buying stocks when they are this expensive has historically led to lower returns, data compiled by Ned Davis Research shows.Marketsread more
Microsoft's effort to catch Amazon Web Services in cloud got a major boost from a new deal with AT&T and an agreement to build out services for 5G.Technologyread more
Uber launches a shopping app with Cargo, an on-the-go convenience store. They already have been working together to put consoles selling snacks in cars.Retailread more
Hedge fund manager Kyle Bass reportedly thinks that U.S. interest rates will plummet toward zero in 2020 as the economy heads for recession.Hedge Fundsread more
If the S&P 500 climbs another 4%, it will have doubled the peak reached in the previous bull market, Michael Santoli notes.Trading Nationread more
Shares of Mylan extended losses Friday after a lawmaker said the Centers for Medicare and Medicaid Services found that Mylan misclassified the lifesaving EpiPen device.
CMS found that Mylan had misclassified the EpiPen as a "non-innovator multiple source drug," or a generic drug.
The error resulted in the overpayment for the drug by the government on a federal and state level through the Medicaid Drug Rebate Program.
For drugs classified as generic, companies pay a 13 percent rebate to Medicaid, compared to the 23 percent rebate for branded drugs.
"The Minnesota Department of Human Services has estimated that this misclassification will cost our state more than $4 million in overpayment this year alone," wrote Senator Klobuchar in a letter to the Centers for Medicare & Medicaid Services (CMS).
Klobuchar demanded a nationwide investigation by CMS.